Tag: NVAX

MTSL Issue 821

MTSL Issue 821 (dated 2/18/16) of the Medical Technology #Stock Letter from Bioinvest includes the #Biotech Sector Analysis as well as updates from the following companies:#INCY #XON #MDCO #NVAX #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Biotech Update Call 1-19-16

Conference Call – Audio Playback (for subscribers only) In light of the current market conditions, Jay Silverman and John McCamant, editors of the Medical Technology Stock Letter, held a conference call today with subscribers to discuss the following: Current market environment and outlook for biotech stocks The overall state of the Biotech Industry – Feedback[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 816

Issue No. 816 (dated 12/3/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #BMRN #XON #MDCO #NKTR #NVAX #OGXI #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 814

Issue No. 814 (dated 10/29/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ALKS, #CBMG, #IMGN, #MDCO, #NVAX, #OGXI, #PCRX, #SGMO, #XON

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 820

MTSL Issue 820 (dated 2/4/16) of the Medical Technology #Stock Letter from Bioinvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ACAD #ALKS #CBMG #INCY #XON #MDCO #NKTR #NVAX

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 815

Issue No. 815 (dated 11/12/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH, #ACAD, #FPRX, #INCY, #ISIS, #MDCO, #NKTR, #NVAX, #OGXI, #XON

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 812

Issue No. 812 (dated 10/1/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH #CBMG #INCY #MDCO #NKTR #NVAX #OGXI #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 819

Issue No. 819 (dated 1/21/16) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ALKS #ANTH #FPRX #INCY #MDCO #NKTR #NVAX #OGXI #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 817

Issue No. 817 (dated 12/17/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH #ALKS #MDCO #NKTR #NVAX #OGXI #PCRX SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Biotech Bets: A Mispriced Trio (11-9-2015)

Recent volatility has created an environment for biotech stocks in which company fundamentals are mispriced relative to their stock prices, according to John McCamant. Here, the editor of The Medical Technology Stock Letter discusses the current state of the biotech market and highlights a trio of well-positioned stocks currently being undervalued by the market.

Posted on by

MTSL Issue 811

Issue No. 811 (dated 9/17/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH #CBMG #FPRX #INCY #MDCO #NVAX #PCRX #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by